Plus therapeutics completes enrollment of cohort 1 respect-lm phase 1/2a trial

Rhenium-186 nanoliposome (186rnl) targeted radiotherapeutic successfully delivered without dose limiting toxicities in initial cohort

PSTV Ratings Summary

PSTV Quant Ranking